Technical Analysis for EXAS - Exact Sciences Corporation

Grade Last Price % Change Price Change
grade D 103.97 0.55% 0.57
EXAS closed up 0.55 percent on Friday, September 20, 2019, on 2.14 times normal volume. Due to the stock's strong downtrend, it may remain oversold for a while. So, if you're looking for a reason to buy, don't put too much weight on it being oversold.

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Strong Up Down Down
See historical EXAS trend table...

Date Alert Name Type % Chg
New Downtrend Bearish 0.00%
Pocket Pivot Bullish Swing Setup 0.00%
Oversold Stochastic Weakness 0.00%
Oversold Stochastic Weakness -1.39%
Lower Bollinger Band Walk Weakness -2.71%
Oversold Stochastic Weakness -2.71%
NR7 Range Contraction -0.42%
Lower Bollinger Band Walk Weakness -0.42%
Stochastic Reached Oversold Weakness -0.42%
Below Lower BB Weakness -0.42%

Older signals for EXAS ...

Get a Trading Assistant

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:
Exact Sciences Corporation, a molecular diagnostics company, focuses on developing diagnostic screening products for the early detection and prevention of colorectal pre-cancer and cancer. The company develops the Cologuard, a non-invasive stool-based DNA colorectal cancer screening test that is designed to detect pre-cancerous lesions or polyps, and each of the four stages of colorectal cancer. Its Cologuard test includes proprietary and patented methods that isolate and analyze the human DNA that are shed into stool every day from the exfoliation of cells that line the colon; and also protein marker to detect blood in the stool, utilizing an antibody-based fecal immunochemical test. The company's stool-based DNA colorectal cancer screening technology also focuses on the inflammatory bowel disease. It has collaboration, license, and purchase agreement with Genzyme Corporation, as well as with Mayo Clinic for developing tests to detect other gastro-intestinal cancers, primarily esophageal and pancreatic cancer. Exact Sciences Corporation was founded in 1995 and is headquartered in Madison, Wisconsin.
Medicine Health Cancer Medical Tests Inflammatory Bowel Disease Colorectal Cancer Pancreatic Cancer Cancer Screening Diagnostic Gastroenterology Mayo Clinic Polyp
Is EXAS a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 1 bullish, 3 bearish and 1 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicator Value
52 Week High 123.99
52 Week Low 53.06
Average Volume 1,667,551
200-Day Moving Average 97.178
50-Day Moving Average 115.3504
20-Day Moving Average 113.255
10-Day Moving Average 106.584
Average True Range 4.0809
ADX 25.2
+DI 13.2168
-DI 35.3754
Chandelier Exit (Long, 3 ATRs ) 111.0673
Chandelier Exit (Short, 3 ATRs ) 112.8327
Upper Bollinger Band 127.1056
Lower Bollinger Band 99.4044
Percent B (%b) 0.16
BandWidth 24.459141
MACD Line -3.5793
MACD Signal Line -2.3324
MACD Histogram -1.2469
Fundamentals Value
Market Cap 12.38 Billion
Num Shares 119 Million
EPS -1.29
Price-to-Earnings (P/E) Ratio -80.60
Price-to-Sales 34.69
Price-to-Book 10.86
PEG Ratio -1.87
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 110.18
Resistance 3 (R3) 109.74 107.24 109.15
Resistance 2 (R2) 107.24 105.66 107.46 108.80
Resistance 1 (R1) 105.60 104.68 106.42 106.04 108.45
Pivot Point 103.10 103.10 103.51 103.32 103.10
Support 1 (S1) 101.46 101.52 102.28 101.90 99.49
Support 2 (S2) 98.96 100.54 99.18 99.14
Support 3 (S3) 97.32 98.96 98.80
Support 4 (S4) 97.76